24-Week efficacy and safety results from the adalimumab effectiveness in psoriatic arthritis trial (ADEPT)

被引：0
作者：
Mease, PJ
Choy, EHS
Gladman, DD
Ritchlin, CT
Ruderman, EM
Steinfeld, SD
Weinberg, MA
机构：
[1] Univ Washington, Sch Med, Seattle, WA USA
[2] Univ London Kings Coll, London WC2R 2LS, England
[3] Univ Toronto, Toronto, ON, Canada
[4] Univ Rochester, Sch Med & Dent, Rochester, NY USA
[5] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[6] Erasme Univ Hosp, B-1070 Brussels, Belgium
[7] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
RHEUMATOLOGY | 2005年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP5
引用
收藏
页码：I3 / I3
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 24-Week Results from the Phase 3, Randomized, Double-blind Clinical Trial for CsDMARD-IR and Bio-IR Patients
    Lidar, Merav
    Aelion, Jacob
    Tarr, Gareth Scott
    Papp, Kim
    Barcomb, Lisa
    Soliman, Ahmed M.
    Lu, Wenjing
    Eldred, Ann
    Ostor, Andrew
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 368 - 369
  • [32] Tocilizumab Monotherapy Compared with Adalimumab Monotherapy in Patients with Rheumatoid Arthritis: Results of a 24-Week Study.
    Kavanaugh, Arthur
    Emery, Paul
    van Vollenhoven, Ronald F.
    Dikranian, Ara H.
    Alten, Rieke
    Klearman, Micki
    Musselman, David
    Agarwal, Sunil
    Green, Jennifer
    Gabay, Cem
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S333 - S334
  • [33] Adalimumab treatment effects on radiographic progression of joint disease in patients with psoriatic arthritis: Results from ADEPT
    Mease, PJ
    Sharp, JT
    Ory, P
    Gladman, DD
    Ritchlin, CT
    Choy, EH
    Weinberg, MA
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 320 - 320
  • [34] Safety and effectiveness of certolizumab pegol in Japanese patients with rheumatoid arthritis: Results from a 24-week post-marketing surveillance study
    Kameda, Hideto
    Nishida, Keiichiro
    Nanki, Toshihiro
    Watanabe, Akira
    Oshima, Yukiya
    Momohara, Shigeki
    MODERN RHEUMATOLOGY, 2023, 33 (03) : 460 - 471
  • [35] Efficacy and safety of ixekizumab at week 24 in biologic-experienced patients with active psoriatic arthritis: summary results
    Marzo-Ortega, H.
    Meroni, P.
    Galindez-Agirregoikoa, E.
    Behrens, F.
    Bradley, A.
    Leage, S. Liu
    Garcia, M.
    Sapin, C.
    Ho, J.
    Constantin, A.
    Hall, S.
    Porsdal, V.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2018, 47 : 43 - 44
  • [36] EFFICACY AND SAFETY OF RISANKIZUMAB FOR ACTIVE PSORIATIC ARTHRITIS, INCLUDING PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC THERAPIES: 24-WEEK RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, KEEPSAKE 2 TRIAL
    Ostor, A.
    Van den Bosch, F.
    Papp, K.
    Asnal, C.
    Blanco, R.
    Aelion, J.
    Alperovich, G.
    Zhang, Y.
    Wang, Z.
    Soliman, A. M.
    Eldred, A.
    Kivitz, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 138 - 139
  • [37] Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study
    Wu, Chan-Yuan
    Wang, Qian
    Shi, Jian
    Zhang, Xiu-Ying
    Du, Rong
    Gu, Jie-Ruo
    Liu, Qi-Huan
    Yu, Jiao
    Xu, Jia-Wei
    Zhang, Yan-Jie
    Zhu, Hao
    Li, Meng-Tao
    Zeng, Xiao-Feng
    RHEUMATOLOGY AND THERAPY, 2023, 10 (06) : 1609 - 1622
  • [38] Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study
    Chan-yuan Wu
    Qian Wang
    Jian Shi
    Xiu-ying Zhang
    Rong Du
    Jie-ruo Gu
    Qi-huan Liu
    Jiao Yu
    Jia-wei Xu
    Yan-jie Zhang
    Hao Zhu
    Meng-tao Li
    Xiao-feng Zeng
    Rheumatology and Therapy, 2023, 10 : 1609 - 1622
  • [39] Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period
    Berenbaum, Francis
    Blanco, Francisco J.
    Guermazi, Ali
    Miki, Kenji
    Yamabe, Takaharu
    Viktrup, Lars
    Junor, Rod
    Carey, William
    Brown, Mark T.
    West, Christine R.
    Verburg, Kenneth M.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (06) : 800 - 810
  • [40] Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial
    Ostor, Andrew
    van den Bosch, Filip
    Papp, Kim
    Asnal, Cecilia
    Blanco, Ricardo
    Aelion, Jacob
    Carter, Kyle
    Stakias, Vassilis
    Lippe, Ralph
    Drogaris, Leonidas
    Soliman, Ahmed M.
    Chen, Michael M.
    Padilla, Byron
    Kivitz, Alan
    RHEUMATOLOGY AND THERAPY, 2024, 11 (03) : 633 - 648
12345